New anti-obesity drug

The anti-obesity drug market, which generates a huge ¥12 trillion market, now includes dual agonists that act on the respective receptors for GLP-1 and glucagon, reducing body fat mass without reducing muscle mass more than GLP-1. High profile!
https://miyata-bio.net/column/0000332/